《大行報告》麥格理下調君實生物(01877.HK)目標價至72.15元 評級「跑贏大市」
麥格理髮表研究報告,下調君實生物(01877.HK)目標價18%至72.15元,維持「跑贏大市」評級。
該行指,公司股價自6月美國暫停供應其與禮來合作之COVID-19的雙抗體療法後已調整40%。該行因此將有關收入在其明年財務預測中剔除。
該行指,公司旗下Toripalimab仍然具前景,雖然與禮來合作受阻,但訂單已轉到其他產品,包括與Regeneron的混合雙抗體,以及近期獲授權的GSK/Vir的單抗藥物VIR-7831,將有助抵銷市場的擔憂,同時相信公司未來將會繼續研發COVID-19的新產品,且未反映於現況。
該行降2021至23年盈利預期68%、73%及89%,以反映對抗體產品貢獻減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.